Randomized trial: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC – AJMC